Promising results from the CLINVO study for Non-Small Cell Lung Cancer patients
Biomarker-directed, multi-drug, phase 1b trial in bladder cancer
The challenges of using biomarkers for immunotherapy
R. Donald Harvey
Results of KEYNOTE-024 trial of pembrolizumab in NSCLC
What is durvalumab’s future as a treatment option in lung cancer?